Comparison
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist in Phase 3 development. Semaglutide is a pure GLP-1 receptor agonist that is FDA-approved and widely prescribed. Adding glucagon agonism to GLP-1 stimulation introduces a thermogenic energy expenditure component to appetite suppression, and research has investigated distinct benefits in metabolic liver disease (MASH) for this combined agonism approach.
| Attribute | Survodutide | Semaglutide |
|---|---|---|
| Class | Dual GLP-1/glucagon receptor agonist (GLP-1Ra/GcgR); investigational | GLP-1 receptor agonist (GLP-1Ra); prescription pharmaceutical |
| Developer | Boehringer Ingelheim / Zealand Pharma (BI 456906) | Novo Nordisk (Ozempic, Wegovy, Rybelsus) |
| Mechanism | GLP-1R agonism (appetite suppression, insulin secretion) plus glucagon receptor agonism (thermogenesis, hepatic lipid metabolism, energy expenditure) | GLP-1R agonism only; stimulates insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite centrally |
| Route | Subcutaneous injection weekly | Subcutaneous injection weekly (Ozempic/Wegovy) or oral daily (Rybelsus) |
| Weight loss (clinical data) | ~19% at 46 weeks in Phase 2 obesity trial (6 mg dose) | ~15% at 68 weeks in STEP-1 trial (2.4 mg Wegovy) |
| MASH research | Phase 3 LIVERAGE trial ongoing; glucagon agonism targets hepatic lipid accumulation directly | Some MASH benefit reported; less direct hepatic mechanism than dual agonists |
| Approval status | Not approved; Phase 3 (SYNCHRONIZE obesity, LIVERAGE MASH) | FDA-approved for T2D (Ozempic, Rybelsus) and obesity (Wegovy) |
| No GIP component | GLP-1 + glucagon only; no GIP receptor agonism (distinguishing from tirzepatide/retatrutide) | GLP-1 only; no GIP or glucagon agonism |
The defining addition in survodutide compared to semaglutide is glucagon receptor agonism. Glucagon has effects that GLP-1 does not: it increases energy expenditure through thermogenesis (brown adipose tissue activation and mitochondrial uncoupling), promotes hepatic fatty acid oxidation, reduces liver fat accumulation, and reduces appetite via central glucagon receptor signalling. Adding this thermogenic and lipolytic dimension to GLP-1-mediated appetite suppression is the theoretical basis for survodutide's potentially superior weight loss and hepatic benefit.
Phase 2 data for survodutide reported approximately 19% weight loss at 46 weeks at the 6 mg dose, compared to semaglutide's ~15% at 68 weeks in STEP-1. This weight loss advantage, if confirmed in Phase 3, would position survodutide between semaglutide (~15%) and tirzepatide (~20%) in the emerging weight loss drug hierarchy. Importantly, survodutide's receptor profile differs from tirzepatide (GLP-1/GIP) and retatrutide (GLP-1/GIP/glucagon), making it a distinct pharmacological entity despite overlapping efficacy territory.
Approval status represents the most consequential practical difference. Semaglutide is FDA-approved and globally available; survodutide is an investigational compound in Phase 3 trials as of the knowledge cutoff, without an approved indication. The SYNCHRONIZE trials (obesity) and LIVERAGE trials (metabolic dysfunction-associated steatohepatitis, MASH) are the primary Phase 3 programs. The MASH indication is of particular research interest because glucagon receptor agonism has direct mechanisms relevant to hepatic lipid accumulation that pure GLP-1 agonists lack.
Glucagon's classical role is counter-regulatory: it raises blood glucose during fasting by stimulating hepatic glycogenolysis and gluconeogenesis. However, glucagon receptors are also expressed in brown adipose tissue, where activation stimulates thermogenesis (energy expenditure as heat), and in the liver, where glucagon signalling promotes fatty acid oxidation and reduces de novo lipogenesis. These hepatic and thermogenic effects are why GLP-1/glucagon dual agonists have generated particular interest for MASH, a condition characterised by hepatic fat accumulation and inflammation.
The challenge with glucagon agonism is glycemic balance. Glucagon raises blood glucose; GLP-1 lowers it through insulin stimulation and glucagon suppression. In a dual agonist, these opposing effects must be balanced to avoid hyperglycemia from the glucagon component. Research into GLP-1/glucagon dual agonists has focused on finding receptor activity ratios that provide metabolic benefits (thermogenesis, hepatic lipid reduction) without worsening glycemia. Survodutide's clinical data suggests this balance is achievable, with no worsening of glycemic parameters in Phase 2 in the doses studied.
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is an area of significant unmet medical need with limited approved pharmacotherapy. GLP-1 agonists including semaglutide have shown liver fat reduction in MASH research. Adding glucagon receptor agonism, with its direct hepatic fatty acid oxidation and lipid-lowering effects, represents a mechanistic rationale for greater hepatic benefit in MASH than pure GLP-1 agonism. The LIVERAGE Phase 3 program is specifically investigating survodutide's effects on MASH histology endpoints (fibrosis resolution, MASH resolution), which would be distinct from semaglutide's approved indications.
Survodutide Phase 2 reported side effects were primarily GI: nausea, vomiting, diarrhea, and decreased appetite. These are consistent with the GLP-1 agonist class. The glucagon component raises a theoretical concern about glycemia and heart rate elevation (glucagon increases heart rate); clinical data from Phase 2 did not show meaningful glycemic worsening or excess cardiovascular events.
Semaglutide commonly reported side effects include nausea, vomiting, diarrhea, and constipation, with GI effects most pronounced during dose escalation. The class rare risk of pancreatitis applies; a theoretical thyroid C-cell concern from rodent data has not translated to clinical evidence of elevated risk in humans at approved doses.
Research contexts consider semaglutide when an FDA-approved GLP-1 agonist is required, when the long safety and efficacy data record of an approved compound is important, or when the research question specifically involves pure GLP-1R agonism as the pharmacological variable. As an approved and available pharmaceutical, semaglutide remains the GLP-1 reference compound against which newer agents are compared.
Research contexts consider survodutide when the specific effects of adding glucagon receptor agonism to GLP-1R stimulation are the variable of interest, when MASH hepatic endpoints are the research focus, or when Phase 3 trial context is relevant. As an investigational compound, survodutide is available only within clinical trial settings or research contexts appropriate to its regulatory status. Semaglutide is a prescription pharmaceutical; its use is governed by applicable medical and regulatory frameworks.
Tirzepatide (Mounjaro/Zepbound) is a GLP-1/GIP dual agonist; it adds GIP receptor agonism but not glucagon agonism. Retatrutide is a triple agonist (GLP-1/GIP/glucagon). Survodutide is a GLP-1/glucagon dual agonist with no GIP component. This makes survodutide distinct from tirzepatide at the receptor level: it targets energy expenditure and hepatic lipid metabolism via glucagon rather than the adipose tissue and incretin-amplifying effects of GIP. The different receptor combinations represent distinct pharmacological profiles despite overlapping weight loss territory.
Metabolic dysfunction-associated steatohepatitis (MASH) is liver inflammation and damage caused by fat accumulation (steatosis) in the liver, associated with obesity and metabolic syndrome. Glucagon receptor activation in the liver promotes fatty acid oxidation and reduces de novo lipogenesis, directly targeting the hepatic fat accumulation that drives MASH. GLP-1 agonism alone reduces liver fat through weight loss and insulin sensitisation; adding glucagon agonism adds a direct hepatic lipid-clearing mechanism. This is why dual GLP-1/glucagon agonists like survodutide have generated particular interest in MASH research compared to pure GLP-1 agonists.
The theoretical concern with glucagon agonism is blood glucose elevation, since glucagon's classical role is counter-regulatory. In survodutide, the GLP-1 component provides insulin stimulation and glucagon suppression that counterbalances the hyperglycemic risk. Phase 2 data did not show meaningful worsening of blood glucose parameters. The molecular design of GLP-1/glucagon dual agonists specifically aims to balance these opposing glycemic effects, though individual responses may vary and the full glycemic safety profile will be characterised in Phase 3 data.
As of the knowledge cutoff, survodutide is in Phase 3 clinical trials for obesity (SYNCHRONIZE program) and MASH (LIVERAGE program). Regulatory submission and potential approval timelines depend on Phase 3 outcomes and regulatory review processes in each jurisdiction. Phase 3 data is expected in the 2025–2026 timeframe, but availability as an approved pharmaceutical would follow regulatory review and approval decisions not yet made as of the knowledge cutoff date.